Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

István Szabadkai

Axel Ullrich

László Örfi

Yixiang Zhang

György Kéri

Robert Torka

Pjotr Knyazev

Kéri György

Lászlo Örfi

Lászl Örfi

Novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family are described herein. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.

Quinoline derivatives as AXL kinase inhibitors

The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases.

Quinolinyloxyphenylsulfonamides

Growing community of inventors

Budapest, Hungary

István Szabadkai